Friedreich Ataxia - Pipeline Review, H2 2019

Friedreich Ataxia - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Friedreich Ataxia - Pipeline Review, H2 2019, provides an overview of the Friedreich Ataxia (Central Nervous System) pipeline landscape.

Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Friedreich Ataxia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Friedreich Ataxia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Friedreich Ataxia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 3, 14, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Friedreich Ataxia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Friedreich Ataxia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Friedreich Ataxia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Friedreich Ataxia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Friedreich Ataxia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Friedreich Ataxia (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Friedreich Ataxia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Friedreich Ataxia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Friedreich Ataxia - Overview
Friedreich Ataxia - Therapeutics Development
Friedreich Ataxia - Therapeutics Assessment
Friedreich Ataxia - Companies Involved in Therapeutics Development
Friedreich Ataxia - Drug Profiles
Friedreich Ataxia - Dormant Projects
Friedreich Ataxia - Discontinued Products
Friedreich Ataxia - Product Development Milestones
Appendix
List of Tables
Table 1: Number of Products under Development for Friedreich Ataxia, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 6: Products under Development by Universities/Institutes, H2 2019
Table 7: Number of Products by Stage and Target, H2 2019
Table 8: Number of Products by Stage and Mechanism of Action, H2 2019
Table 9: Number of Products by Stage and Route of Administration, H2 2019
Table 10: Number of Products by Stage and Molecule Type, H2 2019
Table 11: Friedreich Ataxia - Pipeline by Adverum Biotechnologies Inc, H2 2019
Table 12: Friedreich Ataxia - Pipeline by Agios Pharmaceuticals Inc, H2 2019
Table 13: Friedreich Ataxia - Pipeline by Amylyx Pharmaceutical Corp, H2 2019
Table 14: Friedreich Ataxia - Pipeline by BioElectron Technology Corp, H2 2019
Table 15: Friedreich Ataxia - Pipeline by Biointaxis SL, H2 2019
Table 16: Friedreich Ataxia - Pipeline by BioMarin Pharmaceutical Inc, H2 2019
Table 17: Friedreich Ataxia - Pipeline by Biovista Inc, H2 2019
Table 18: Friedreich Ataxia - Pipeline by Cardero Therapeutics Inc, H2 2019
Table 19: Friedreich Ataxia - Pipeline by Chondrial Therapeutics LLC, H2 2019
Table 20: Friedreich Ataxia - Pipeline by Exicure Inc, H2 2019
Table 21: Friedreich Ataxia - Pipeline by Fratagene Therapeutics Srl, H2 2019
Table 22: Friedreich Ataxia - Pipeline by Fulcrum Therapeutics Inc, H2 2019
Table 23: Friedreich Ataxia - Pipeline by Ixchel Pharma LLC, H2 2019
Table 24: Friedreich Ataxia - Pipeline by Jupiter Orphan Therapeutics Inc, H2 2019
Table 25: Friedreich Ataxia - Pipeline by Metro International Biotech LLC, H2 2019
Table 26: Friedreich Ataxia - Pipeline by Minoryx Therapeutics sl, H2 2019
Table 27: Friedreich Ataxia - Pipeline by Panorama Research Inc, H2 2019
Table 28: Friedreich Ataxia - Pipeline by Pfizer Inc, H2 2019
Table 29: Friedreich Ataxia - Pipeline by PTC Therapeutics Inc, H2 2019
Table 30: Friedreich Ataxia - Pipeline by Reata Pharmaceuticals Inc, H2 2019
Table 31: Friedreich Ataxia - Pipeline by Retrotope Inc, H2 2019
Table 32: Friedreich Ataxia - Pipeline by Seelos Therapeutics, Inc., H2 2019
Table 33: Friedreich Ataxia - Pipeline by STATegics Inc, H2 2019
Table 34: Friedreich Ataxia - Pipeline by Voyager Therapeutics Inc, H2 2019
Table 35: Friedreich Ataxia - Dormant Projects, H2 2019
Table 36: Friedreich Ataxia - Discontinued Products, H2 2019
List of Figures
Figure 1: Number of Products under Development for Friedreich Ataxia, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Targets, H2 2019
Figure 5: Number of Products by Stage and Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Molecule Types, H2 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook